SCHEMBL2393760

SCHEMBL2393760

NC(=O)Cc1ccccc1-c1cccc(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 4/20 0.56
CHRM3 P20309 2/20 0.56
CYP2C19 P33261 2/20 0.46
PTGER1 P34995 2/20 0.44
PTGER4 P35408 2/20 0.44
PTGER3 P43115 2/20 0.44
PTGER2 P43116 2/20 0.44
PDE4B Q07343 2/20 0.44
CYP3A4 P08684 1/20 0.44
SLC9A1 P19634 2/20 0.43
MCL1 Q07820 1/20 0.42
BAD Q92934 1/20 0.42
PARP1 P09874 1/20 0.42
ACLY P53396 1/20 0.41
DCLRE1B Q9H816 1/20 0.41
KCNJ5 P48544 1/20 0.41
KCNJ3 P48549 1/20 0.41
NUDT1 P36639 1/20 0.41
RORB Q92753 1/20 0.41
HSP90AA1 P07900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890768 0.88 PDE4B (0.45) CHRM1CHRM3CYP2C19PDE4BCYP3A4
SCHEMBL2391279 0.87 CYP2C19 (0.48) CHRM1CHRM3CYP2C19SLC9A1ACLY
SCHEMBL9890642 0.86 CHRM1 (0.57) CHRM1CHRM3PTGER1PTGER4PTGER3
SCHEMBL6098745 0.84 PTGER4 (0.62) PTGER1PTGER4PTGER3PTGER2ACLY
SCHEMBL9890733 0.82 ICMT (0.44) CHRM1CHRM3CYP2C19PDE4BCYP3A4
SCHEMBL2395113 0.82 CHRM1 (0.45) CHRM1CHRM3CYP2C19PDE4BCYP3A4
SCHEMBL6184923 0.82 CYP2C19 (0.64) CYP2C19ACLY
SCHEMBL9295512 0.81 CHRM1 (0.54) CHRM1CHRM3CYP2C19PTGER1PTGER4
SCHEMBL1547038 0.81 KMT2A (0.56) CYP2C19PTGER1PTGER4PTGER3PTGER2
SCHEMBL2392257 0.81 ICMT (0.54) PTGER1PTGER4PTGER3PTGER2SLC9A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US claimed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP claimed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US claimed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CHRM1 340/4885CHRM3 298/4885CYP2C19 240/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CHRM1 340/4885CHRM3 298/4885CYP2C19 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.